TMO · 8-K · 20261021PR000173

Revenue Performance and Mix

THERMO FISHER SCIENTIFIC INC. · 2026-10-21 · Importance 49 · Surprise 32 · From source text

Third-quarter 2026 revenue increased 9% to $12.137 billion from $11.122 billion a year earlier, with organic growth of 6%. Acquisitions and divestitures contributed 3 percentage points to growth, while currency translation contributed 0 points. Laboratory Products and Biopharma Services revenue grew 15% to $6.863 billion and increased its mix to 56.5% from 53.7%; Life Sciences Solutions revenue grew 5% to $2.719 billion. Analytical Instruments revenue rose 6% to $2.002 billion, while Specialty Diagnostics revenue declined 6% to $1.098 billion.

Key facts

• Thermo Fisher Scientific said it would provide updated 2026 financial guidance during its earnings conference call on October 21, 2026, at 7:00 a.m. Eastern Time. source
• Thermo Fisher Scientific's third-quarter 2026 revenue was $12.14 billion, up 9% year over year, with 6% organic revenue growth. source
• Thermo Fisher Scientific's revenue growth for the nine months ended September 26, 2026 was 9%, including 4% organic revenue growth, 4% from acquisitions/divestitures and 1% from currency translation. source
• Thermo Fisher Scientific's third-quarter 2026 adjusted EPS was $6.68, up 15% year over year. source
• Thermo Fisher Scientific's third-quarter 2026 GAAP diluted EPS was $4.64, up 9% year over year. source

Impact estimates